Tizanidine Hydrochloride Capsule, Gelatin Coated
Product Images NDC 0591-2789
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 0591-2789). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1: Mean Tizanidine Concentration Vs. Time Profiles For Tizanidine Hydrochloride Tablets And Capsules (2 × 4 mg) Under Fasted And Fed Conditions (Image 2)
Figure 2: Single Dose Study—mean Change In Muscle Tone From Baseline As Measured By The Ashworth Scale ± 95% Confidence Interval (a Negative Ashworth Score Signifies An Improvement In Muscle Tone From Baseline) (Image 3)
Figure 3: Seven Week Study—mean Change In Muscle Tone 0.5–2.5 Hours After Dosing As Measured By The Ashworth Scale ± 95% Confidence Interval (a Negative Ashworth Score Signifies An Improvement In Muscle Tone From Baseline) (Image 4)
1 (Image 5)
1 (Image 6)
1 (Image 7)
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.